By Fineline Cube Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the dosing of the first subject in a Phase I clinical trial in China for HLX319, its proposed biosimilar to Roche’s Phesgo (trastuzumab/pertuzumab). HLX319 is a subcutaneous injection for the treatment of HER2-positive breast cancer, combining trastuzumab and pertuzumab with Henlius’s proprietary recombinant human hyaluronidase, HLXTE-HAase02.
Clinical Trial Design
| Feature | Detail |
|---|---|
| Study Type | Randomized, double-blind, parallel-controlled, single-dose |
| Population | Healthy Chinese male subjects |
| Arms | 1:1 randomization to HLX319 or reference Phesgo |
| Administration | Single subcutaneous injection in the thigh (~5 minutes) |
| Primary Endpoints | PK parameters: Cmax, AUC0-∞ |
| Secondary Endpoints | Additional PK, safety, tolerability, immunogenicity |
Product Profile & Differentiation
- Target Indications: Adjuvant/neoadjuvant treatment of HER2-positive early or locally advanced breast cancer; treatment of metastatic breast cancer.
- Composition: Combines the active ingredients trastuzumab and pertuzumab with HLXTE-HAase02, a novel recombinant human hyaluronidase independently developed by Henlius to facilitate subcutaneous delivery.
- Reference Product: Roche’s Phesgo, which has demonstrated significant advantages over intravenous administration, including a much shorter administration time (minutes vs. hours).
Strategic Implications
- Biosimilars Leadership: This trial marks a critical step in Henlius’s strategy to become a leader in complex oncology biosimilars, targeting one of Roche’s most successful and clinically important combination products.
- Subcutaneous Advantage: By replicating the subcutaneous format, HLX319 aims to offer the same patient-centric benefits as Phesgo—dramatically reduced clinic time and improved convenience—potentially at a lower cost.
- Vertical Integration: The use of Henlius’s own HLXTE-HAase02 hyaluronidase showcases the company’s commitment to controlling its entire value chain, from active pharmaceutical ingredients to key excipients, ensuring supply security and quality.
- Market Opportunity: A successful biosimilar launch in China would provide more affordable access to this standard-of-care dual HER2 blockade therapy, addressing a major unmet need in a large patient population.
Market Context
- High-Value Target: Phesgo represents a multi-billion dollar global franchise for Roche. Biosimilars to this product are among the most sought-after in the industry due to their high clinical and commercial value.
- Chinese Innovation: Henlius’s development of its own hyaluronidase underscores the growing sophistication of Chinese biopharma firms in tackling complex formulation challenges associated with advanced biologics.
- Path Forward: The Phase I PK study is the foundational step to demonstrate biosimilarity. Positive results will pave the way for confirmatory Phase III trials in the target patient population.
Forward-Looking Statements
This brief reports on the initiation of a Phase I clinical trial. The development of HLX319 is subject to the risks inherent in clinical drug development, including the possibility of failure to demonstrate biosimilarity or an acceptable safety profile. There can be no assurance of regulatory approval.-Fineline Info & Tech